P38α regulates SERCA2a function

Journal of Molecular and Cellular Cardiology

Volumn 67, Issue , 2014, Pages 86-93

  Kaikkonen, Leena ^a   Magga, Johanna ^a   Ronkainen, Veli Pekka ^a   Koivisto, Elina ^a   Perjes, Ábel ^a   Chuprun, J Kurt ^b   Vinge, Leif Erik ^c,d,e   Kilpiö, Teemu ^a   Aro, Jani ^a   Ulvila, Johanna ^a   Alakoski, Tarja ^a   Bibb, James A ^f   Szokodi, Istvan ^g   Koch, Walter J ^b   Ruskoaho, Heikki ^a,h   Kerkelä, Risto ^a,i  

^a UNIVERSITY OF OULU   (Finland)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF PÉCS   (Hungary)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cardiac contractility; P38; Phospholamban; SERCA2a

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; SMALL INTERFERING RNA; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; INOTROPISM; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAT; RNA INTERFERENCE;

ADULT MOUSE VENTRICULAR MYOCYTE; ADULT RAT VENTRICULAR MYOCYTE; AMVM; ARVM; CARDIAC CONTRACTILITY; DN; DOMINANT NEGATIVE; ENDOTHELIN-1; ET-1; G PROTEIN COUPLED RECEPTOR KINASE; GRK; I-1; INHIBITOR-1; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; NEONATAL RAT VENTRICULAR MYOCYTE; NRVM; OA; OKADAIC ACID; P38; PHOSPHOLAMBAN; PLB; PP1; PP2A; PROTEIN PHOSPHATASE-1; PROTEIN PHOSPHATASE-2A; SARCO/ENDOPLASMIC RETICULUM CA(2+) ATPASE; SERCA2A;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; ENZYME ACTIVATION; MUSCLE CONTRACTION; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RNA INTERFERENCE; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84892888945     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.12.005     Document Type: Article

References (34)

1. Eisner D., Bode E., Venetucci L., Trafford A. Calcium flux balance in the heart. J Mol Cell Cardiol 2013, 58:110-117.
2. Bers D.M. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008, 70:23-49.
3. Kranias E.G., Hajjar R.J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012, 110:1646-1660.
4. Wittkopper K., Dobrev D., Eschenhagen T., El-Armouche A. Phosphatase-1 inhibitor-1 in physiological and pathological beta-adrenoceptor signalling. Cardiovasc Res 2011, 91:392-401.
5. Baines C.P., Molkentin J.D. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 2005, 38:47-62.
6. Rose B.A., Force T., Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 2010, 90:1507-1546.
7. Kerkela R., Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy?. J Am Coll Cardiol 2006, 48:556-558.
8. Liao P., Wang S.Q., Wang S., Zheng M., Zheng M., Zhang S.J., et al. p38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 2002, 90:190-196.
9. Zheng M., Zhang S.J., Zhu W.Z., Ziman B., Kobilka B.K., Xiao R.P. Beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes. J Biol Chem 2000, 275:40635-40640.
10. Bellahcene M., Jacquet S., Cao X.B., Tanno M., Haworth R.S., Layland J., et al. Activation of p38 mitogen-activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor. J Am Coll Cardiol 2006, 48:545-555.
11. Auger-Messier M., Accornero F., Goonasekera S.A., Bueno O.F., Lorenz J.N., van Berlo J.H., et al. Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy. Circ Res 2013, 112:48-56.
12. Kerkela R., Ilves M., Pikkarainen S., Tokola H., Ronkainen V.P., Majalahti T., et al. Key roles of endothelin-1 and p38 MAPK in the regulation of atrial stretch response. Am J Physiol Regul Integr Comp Physiol 2011, 300:R140-R149.
13. Vahebi S., Ota A., Li M., Warren C.M., de Tombe P.P., Wang Y., et al. p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res 2007, 100:408-415.
14. Szokodi I., Kerkela R., Kubin A.M., Sarman B., Pikkarainen S., Konyi A., et al. Functionally opposing roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the regulation of cardiac contractility. Circulation 2008, 118:1651-1658.
15. Andrews C., Ho P.D., Dillmann W.H., Glembotski C.C., McDonough P.M. The MKK6-p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT. Cardiovasc Res 2003, 59:46-56.
16. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 2001, 98:12283-12288.
17. Ungerer M., Bohm M., Elce J.S., Erdmann E., Lohse M.J. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
18. Pitcher J.A., Tesmer J.J., Freeman J.L., Capel W.D., Stone W.C., Lefkowitz R.J. Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J Biol Chem 1999, 274:34531-34534.
19. Bibb J.A., Nishi A., O'Callaghan J.P., Ule J., Lan M., Snyder G.L., et al. Phosphorylation of protein phosphatase inhibitor-1 by Cdk5. J Biol Chem 2001, 276:14490-14497.
20. El-Armouche A., Bednorz A., Pamminger T., Ditz D., Didie M., Dobrev D., et al. Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun 2006, 346:700-706.
21. Boyce M., Bryant K.F., Jousse C., Long K., Harding H.P., Scheuner D., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
22. Weinbrenner C., Baines C.P., Liu G.S., Armstrong S.C., Ganote C.E., Walsh A.H., et al. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation 1998, 98:899-905.
23. Deshmukh P.A., Blunt B.C., Hofmann P.A. Acute modulation of PP2a and troponin I phosphorylation in ventricular myocytes: studies with a novel PP2a peptide inhibitor. Am J Physiol Heart Circ Physiol 2007, 292:H792-H799.
24. Junttila M.R., Li S.P., Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008, 22:954-965.
25. Bers D.M. Cardiac excitation-contraction coupling. Nature 2002, 415:198-205.
26. Kho C., Lee A., Hajjar R.J. Altered sarcoplasmic reticulum calcium cycling-targets for heart failure therapy. Nat Rev Cardiol 2012, 9:717-733.
27. Simmerman H.K., Collins J.H., Theibert J.L., Wegener A.D., Jones L.R. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J Biol Chem 1986, 261:13333-13341.
28. Nicolaou P., Hajjar R.J., Kranias E.G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 2009, 47:365-371.
29. Carr A.N., Schmidt A.G., Suzuki Y., del MF Sato Y., Lanner C., et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 2002, 22:4124-4135.
30. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 2005, 96:756-766.
31. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004, 10:248-254.
32. Wittkopper K., Fabritz L., Neef S., Ort K.R., Grefe C., Unsold B., et al. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 2010, 120:617-626.
33. Layland J., Grieve D.J., Cave A.C., Sparks E., Solaro R.J., Shah A.M. Essential role of troponin I in the positive inotropic response to isoprenaline in mouse hearts contracting auxotonically. J Physiol 2004, 556:835-847.
34. Inesi G., Kurzmack M., Lewis D. Kinetic and equilibrium characterization of an energy-transducing enzyme and its partial reactions. Methods Enzymol 1988, 157:154-190.